Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript

Mitchell Steiner: But the fact that we’re measuring physical function, we know the FDA likes how patient feels, functions, and survives. And so, that’s why the stair climb test, which is a key component of the Phase 2b, is important because I think that will also influence how we think about endpoints in a Phase 3. Ultimately, we think Enobosarm is a kind of a programmatic molecule, meaning that you’re looking at rescue. You’re looking at decreasing doses of GLP-1s. You’re looking at being used in combination with the whole population, used in combination with a at-risk population, could potentially be used in combination with a myostatin inhibitor. It can potentially be used. So, I think this can be pretty interesting. And so, we are active in trying to find a partner that has the resources to allow us to explore all these possibilities.

Yi Chen: Thank you.

Operator: Ladies and gentlemen, this concludes our question-and-answer session. I would like to turn the conference back over to Mitchell Steiner for any closing remarks.

Mitchell Steiner: Thank you, operator. I appreciate everybody who joined us on today’s call, and we’re very, very excited about the prospects of Enobosarm. I look forward to updating you on our progress in the next investors call. Thank you.

Operator: A digital replay of the conference call will be available beginning approximately noon Eastern Time today, February 8, by dialing 1-877-344-7529 in the US, and 1-412-317-0088 internationally. You’ll be prompted to enter the replay access code, which will be 8260066. Please record your name and company when joining the conference. The call has now concluded. Thank you for attending today’s discussion.